Growth Factor-Induced Mobilization of Cardiac Progenitor Cells Reduces the Risk of Arrhythmias, in a Rat Model of Chronic Myocardial Infarction

Leonardo Bocchi1,2, Monia Savi1,9, Gallia Graiani2, Stefano Rossi1, Aldo Agnetti3,7, Francesca Stillitano4, Costanza Lagrasta2,7, Silvana Baruffi1, Roberta Berni1, Caterina Frati3, Mario Vassalle5, Umberto Squarci3,7, Elisabetta Cerbai6, Emilio Macchi1,7, Donatella Stilli1,7, Federico Quaini6,7, Ezio Musso1,7*

1 Dipartimento di Biologia Evolutiva e Funzionale, Università di Parma, Parma, Italy, 2 Dipartimento di Patologia e Medicina di Laboratorio, Università di Parma, Parma, Italy, 3 Dipartimento dell’Età Evolutiva, Università di Parma, Parma, Italy, 4 Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Firenze, Italy, 5 Department of Physiology and Pharmacology, SUNY, Downstate Medical Center, Brooklyn, New York, United States of America, 6 Dipartimento di Medicina Interna e Scienze Biomediche, Università di Parma, Parma, Italy, 7 Centro Interdipartimentale Cellule Staminali Cardiache (CISTAC), Università di Parma, Parma, Italy

Abstract

Heart repair by stem cell treatment may involve life-threatening arrhythmias. Cardiac progenitor cells (CPCs) appear best suited for reconstituting lost myocardium without posing arrhythmic risks, being commissioned towards cardiac phenotype. In this study we tested the hypothesis that mobilization of CPCs through locally delivered Hepatocyte Growth Factor and Insulin-Like Growth Factor-1 to heal chronic myocardial infarction (MI), lowers the proneness to arrhythmias. We used 133 adult male Wistar rats either with one-month old MI and treated with growth factors (GFs, n = 60) or vehicle (V, n = 55), or sham operated (n = 18). In selected groups of animals, prior to and two weeks after GF/V delivery, we evaluated stress-induced ventricular arrhythmias by telemetry-ECG, cardiac mechanics by echocardiography, and ventricular excitability, conduction velocity and refractoriness by epicardial multiple-lead recording. Invasive hemodynamic measurements were performed before sacrifice and eventually the hearts were subjected to anatomical, morphometric, immunohistochemical, and molecular biology analyses. When compared with untreated MI, GFs decreased stress-induced arrhythmias and concurrently prolonged the effective refractory period (ERP) without affecting neither the duration of ventricular repolarization, as suggested by measurements of QTC interval and mRNA levels for K-channel α-subunits Kv4.2 and Kv4.3, nor the dispersion of refractoriness. Further, markers of cardiomyocyte reactive hypertrophy, including mRNA levels for K-channel α-subunit Kv1.4 and β-subunit KChIP2, interstitial fibrosis and negative structural remodeling were significantly reduced in peri-infarcted/remote ventricular myocardium. Finally, analyses of BrdU incorporation and distribution of connexin43 and N-cadherin indicated that cytokines generated new vessels and electromechanically-connected myocytes and abolished the correlation of infarct size with deterioration of mechanical function. In conclusion, local injection of GFs ameliorates electromechanical competence in chronic MI. Reduced arrhythmogenesis is attributable to prolongation of ERP resulting from improved intercellular coupling via increased expression of connexin43, and attenuation of unfavorable remodeling.

Citation: Bocchi L, Savi M, Graiani G, Rossi S, Agnetti A, et al. (2011) Growth Factor-Induced Mobilization of Cardiac Progenitor Cells Reduces the Risk of Arrhythmias, in a Rat Model of Chronic Myocardial Infarction. PLoS ONE 6(3): e17750. doi:10.1371/journal.pone.0017750

Editor: Piero Anversa, Brigham and Women’s Hospital, United States of America

Received January 25, 2011; Accepted February 13, 2011; Published March 18, 2011

Copyright: © 2011 Bocchi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by the following grants: Italian Ministry of Education, University and Research PRIN 062944 2005, European Commission CORDIS FP7-BIOSCENT, NMP-214539 2007, Italian Ministry of Health THEAPPL 2008, and funding by “Fondazione Cassa di Risparmio di Parma”, “Ente Cassa di Risparmio di Firenze”, “Compagnia di San Paolo”, and “Istituto Nazionale di Ricerche Cardiovascolari.” The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: ezio.musso@unipr.it

† These authors contributed equally to this work.

Introduction

During the last decade, a growing number of experimental and clinical observations have raised the possibility of treating cardiac damage through the direct repairing ability or the developmental plasticity of stem cells [1]. Although not generally agreed, therapies based on the mobilization/injection of several types of stem cells have been shown to ameliorate the mechanical function and perfusion in ischemic cardiomyopathy [2–4].

A few clinical and experimental studies have addressed the issue of the electrophysiological effects of implantation, homing, engraftment and differentiation of regenerating cells within the damaged myocardium [5–9]. The improvement of cardiac mechanical function by stem cell based treatments can be associated with increase, reduction or no changes in the risk of arrhythmias [5–9]. Often, the occurrence of arrhythmias is negatively correlated with the ability of the newly formed tissue to adopt a cardiac fate or to couple electrically with the spared myocardium [10–15]. The heart contains several cohorts of resident cardiac progenitor cells (CPCs) which have been characterized by different groups [16–22] and are considered to be responsible for tissue
homeostasis [23]. Because CPCs are intrinsically programmed to generate myocardium, they appear best suited for the complex task of reconstituting tissue that is lost with a myocardial infarction [24] and restoring the blood supply in the damaged area [25]. These properties of CPCs would be expected to improve the organization and functional integration of newly formed tissues with the spared tissue, minimizing heterogeneous electrical organization and functional integration of newly formed tissues [10–15]. Thus, mediating the heart promoted by CPCs can be an appropriate substrate to explore the proarrhythmic or antiarrhythmic consequences of stem cell based myocardial regeneration.

CPCs have been reported to express c-Met and insulin-like growth factor-1 (IGF-1) receptors and synthesize and secrete the corresponding ligands, hepatocyte growth factor (HGF) (which mobilizes CPCs) and IGF-1 (which promotes their survival and proliferation) [26]. In infarcted hearts of dogs [27], mice [26], and rats [28], the intramyocardial injection of HGF and IGF-1 enhanced the translocation of CPCs from the surrounding myocardium to the dead tissue and their viability and growth within the damaged area, fostering cardiac regeneration and improving mechanical function. In the present study, we tested the hypothesis that activating the lineage commitment and progeny formation of resident CPCs, via the HGF/IGF-1-receptor systems, can also ameliorate the electrical competence of the infarcted heart, in a rat model of chronic myocardial infarction (MI). Importantly, post-MI ventricular remodeling contributes to end stage heart failure [29], and lethal arrhythmias are responsible for up to half the deaths in heart failure [30].

By following an approach from the intact animal to tissue, cellular, and molecular levels, we found that repair of chronic MI by cytokine treatment significantly reduced the occurrence of arrhythmias. GFs also promoted the development of new myocardial tissue, attenuated negative structural remodeling, and partially restored mechanical function. The amelioration in cardiac electrical stability appeared to include a prolongation of the effective refractory period without changes in the duration of the recovery process attributed to a better intercellular coupling, and positive ventricular remodeling.

**Methods**

A detailed description of the methods is provided in the supporting information (File S1). This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institute of Health. The protocol was approved by the Veterinary Animal Care and Use Committee of the University of Parma and conforms to the National Ethical Guidelines of the Italian Ministry of Health (Permit number: 41/2009-B).

All surgery was performed under anesthesia (ketamine+medetomidine or droperidol+pentanyl citrate), and all efforts were made to minimize suffering.

**Animal population**

Two hundred and seven male Wistar rats, aged 12–14 weeks and weighing 300–350 g, were subjected either to myocardial infarction (MI group) or to sham operation (SO group). Four weeks later, all animals were treated with HGF+IGF-1 (GF) or vehicle (V) and assigned to the following subgroups: MI+GF, MI+V and SO+V. Fifty four rats died in the peri-operative periods and 20 additional rats, assigned to the MI+GF or MI+V groups, were excluded from the study because infarction could not be clearly detected at autopsy, leaving a total of 133 rats.

**Outline of the experimental protocols**

The experimental design and measurements performed in the study are summarized in Table S1.

**In vivo studies.** The occurrence of spontaneous and stress-induced arrhythmias in conscious, freely moving rats was evaluated by Telemetry-ECG recording (TE rats, including 22 MI+GF, 23 MI+V, and 15 SO+V animals), prior to and at 15 days after GF or V (GF/V) administration. At those times, cardiac mechanical function was also evaluated by echocardiography. Invasive hemodynamic measurements were performed before sacrifice. Simultaneously with GF/V injection, selected subgroups of TE rats (MI+GF: n = 14 and MI+V: n = 11), were treated with 5-Bromo-2’-deoxyuridine (BrdU) which in vivo is metabolically converted to BrdU (5-Bromo-2’-deoxyuridine), to evaluate the cumulative amount of cell proliferation. Conduction velocity, excitability, refractoriness, dispersion of refractoriness and QT interval duration were measured by Epicardial Multiple-lead recording (EM rats) in an additional 24 MI+GF and 19 MI+V animals.

**Cardiac anatomy and morphometric analyses.** Hearts obtained from TE and EM rats were perfusion fixed: (i) to ascertain myocardial infarction (all animals), and (ii) to evaluate Left Ventricular (LV) anatomical changes and infarct size, and to carry out morphometric and immunohistochemical analyses (selected subgroups of TE rats).

**Molecular studies.** In 30 additional animals, two weeks after GF/V injection the heart was excised and immediately frozen for Molecular Biology evaluation (MB rats) which included electrophoretic and immunoblot assays (5 MI+GF and 5 MI+V animals) and quantitative RT-PCR measurements (3 SO+V, 9 MI+GF and 8 MI+V animals).

**Telemetry-ECG data acquisition and processing and stress-induced sympathetic stimulation**

A miniaturized telemetry-ECG transmitter was chronically implanted in TE rats under anesthesia, as previously described [31]. A 15-minute telemetry-ECG recording was performed in experimental animals when alone and undisturbed in their home cage (baseline period) and again when subjected to stress-induced sympathetic stimulation (stress period) [32]. Telemetry-ECGs were processed off-line for evaluating the incidence of ventricular arrhythmias, heart rate (1/R-R interval), and time domain indexes of heart rate variability (SDRR: standard deviation of average R-R interval; r-MSSD: root mean square of successive R-R interval square differences), as indirect measurements of the autonomic input to the heart [33].

**Myocardial infarction**

In MI animals under anesthesia and artificial ventilation, a thoracotomy via the third left-intercostal space was performed and the left coronary artery was ligated. The chest was then closed, the pneumothorax was reduced by suction of air and fluid and the rats were allowed to recover. In SO rats the ligature around the coronary artery was not tied.

**Growth factor and BrdC administration**

Four weeks after coronary artery ligation, a second left lateral thoracotomy was performed in all animals. In MI+GF rats, GFs were injected in six intramura1 sites: near the left atrium, between the atrium and the infarct and at four opposite sites of the border zone [26]. The concentration of IGF-1 was constant (200 ng/mL) whereas HGF was administered at increasing concentrations from the atrium to the border zone (50, 100, 200 ng/mL). In MI+V and...
SO+V rats, corresponding regions of the heart were injected with vehicle. In MI+GF animals, Rhodamine spheres were added to the solutions (v/v 5%) to mark the injection sites.

In BrdC treated rats, a continuous infusion of BrdC (0.6 mol/L) was performed until sacrifice (two weeks) by an osmotic pump implanted subcutaneously in the inter-scapular region. The long infusion time prompted us to use BrdC rather than the most commonly employed BrdU because of the nearly six-fold higher solubility of BrdC.

Echocardiography

Serial echocardiograms were obtained from TE rats under anesthesia. Two-dimensional (2-D) and M-mode images were recorded from modified parastral long axis and parastral short axis views. Systolic and diastolic morpho-functional parameters were evaluated using standard methods [34].

Invasive hemodynamics

In anesthetized TE rats, systolic and diastolic arterial blood pressures were recorded by means of a microtip pressure transducer inserted into the right carotid artery. The catheter was then advanced into the left ventricle to measure left ventricular systolic and end-diastolic pressures, and +/− dP/dt, in the closed-chest preparation.

Epicardial multiple-lead recording

EM rats under anesthesia and artificial respiration were subjected to left thoracotomy. A 5×8 or 8×8 row and column electrode array [35] (see Fig. S1A–B), was positioned over the infarcted region and the surrounding areas. Epicardial unipolar electrograms (EGs) were recorded during sinus rhythm or specific pacing protocols in order to determine: (i) conduction velocity at electrograms (EGs) were recorded during sinus rhythm or specific electrode array [35] (see Fig. S1A–B), was positioned over the equatorial slice embedded in paraffin, five-micrometer thick sections were cut and used for morphometric and immunohistochemical analyses.

Cardiac anatomy

In each heart, after perfusion with 10% buffered formalin, the left and right ventricular weights and LV chamber volume were determined. The LV diameter and wall thickness were computed on the equatorial slice. The LV chamber volume was calculated according to the Dodge equation [39]. Subsequently, from the equatorial slice embedded in paraffin, five-micrometer thick sections were cut and used for morphometric and immunohistochemical analyses.

Morphometric analysis

Infarct size was measured by calculating the fraction of myocytes lost as a result of coronary occlusion [40–41]. Myocardial sections stained with Masson’s trichrome were analyzed by optical microscopy to assess the volume fraction of myocytes and perivascular and interstitial fibrosis, according to a procedure previously described [42].

Immunohistochemical analysis

Sections from BrdC treated rat hearts with comparable infarct size were analyzed to determine: (i) the expression and spatial distribution of connexin43 (Cx43) and N-cadherin, (ii) the incidence of c-kit+ CPCs, and (iii) the fraction of nuclei labeled by BrdU, in the infarcted, peri-infarcted and remote LV myocardium. The amount of newly formed myocardium was computed by calculating: (i) the number and size of small α-sarcomeric actin positive (α-SARC+) myocytes and (ii) the number of resistance arterioles and capillaries labeled by α-smooth muscle actin (α-SMA) and von Willebrand Factor (vW) respectively, according to a methodology previously employed [41].

Biochemical and Molecular Biology analyses

Immediately after death, left and right ventricles were excised from the heart of 30 MB rats (see Table S1), weighed and immediately frozen at −80°C.

Electrophoretic and immunoblot assay. The infarcted and non-infarcted portions of the left ventricles obtained from 5 MI+GF and 5 MI+V hearts were used for immunoblot assay of Cx43.

Quantification of Kv1.4, Kv4.2, Kv4.3 and KChIP2 transcripts. In 3 SO+V, 9 MI+GF and 8 MI+V animals, total RNA was harvested from frozen tissue samples using a column-based extraction method. Gene expression was evaluated by reverse transcription quantitative polymerase chain reaction (RT-qPCR). Real-Time PCR for Kv1.4, Kv4.2, Kv4.3 and KChIP2 was performed using an ABI Prism 7500 Sequence Detection System with TaqMan gene expression assays.

Statistical analysis.

The SPSS statistical package was used (SPSS, Chicago, IL, USA, 17th version). Normal distribution of variables was checked by means of the Kolmogorov-Smirnov test. Statistics of variables normally distributed (all variables except baseline arrhythmias) included mean ± standard error (SE), paired and unpaired Student’s t test, and one-way analysis of variance (post-hoc analysis: Games-Howell test and Tukey test when appropriate).

Results

1) Electrical function

Telemetry-ECG recording. R-R interval, SDRR and r-MSSD during baseline ECG recordings had similar values in all groups (R-R: approximately 175 ms, on average; SDRR: 11 ms; r-MSSD: 4 ms), before and after GF/V injection. Stress procedure generally increased heart rate (1/R-R interval) by about 30% and reduced SDRR and r-MSSD by about 40% and 30% respectively (p<0.01), as a result of the enhanced sympathetic activity brought about by the social challenge [32]. The effects of stress were similar before and after GF/V injection in each animal group, suggesting that GFs did not affect the autonomic input to the regenerated heart.

In all animals, ventricular arrhythmias mostly consisted of isolated premature beats and a few salvos. Arrhythmia vulnerability was evaluated as the number of ventricular arrhythmic events (VAEs) during the 15-minute baseline and stress periods. Before GF/V injection, VAEs were negligible during baseline in all groups (range 0–6 events). Stress increased VAEs in both SO and MI rats (p<0.01) although the increment was about two-fold higher in MI animals (p<0.05 vs. SO, Fig. 1A–B). Two weeks after injection, baseline-VAEs remained unchanged in all groups while stress-VAEs were markedly reduced in MI+GF rats (p<0.05) but not in SO+V and MI+V animals (Fig. 2). Thus, cytokine treatment lowered the proneness to arrhythmias triggered by stress-induced
sympathetic stimulation in conscious animals with chronic myocardial infarction. Importantly, this procedure mimics stressful conditions encountered by social animals in everyday life.

**Epicardial multiple lead recording.** To measure excitability, 121, 120 and 114 Strength-Duration (S-D) curves and as many Rheobase (Rh) and Chronaxie (Chr) values (see Fig. S1F) were determined in the MI, MI+V and MI+GF groups respectively. Before injection, Rh and Chr in MI animals were 114±10 \( \mu \)A and 1.2±0.04 ms respectively. Cytokines shifted upward and to the right S-D curves and concurrently Rh and Chr values in MI+GF rats were slightly higher than those measured in MI+V group, suggesting a tendential reduction in excitability (Fig. 3A–B).

Given the limited number of electrodes of the 5x5 array, no reliable conduction velocity (CV) measurements could be performed in the MI rats and only post-injection data were collected in the MI+V and MI+GF groups. CV was computed longitudinally (CV-l) and transversally (CV-t) to fiber orientation (see Fig. S1E) at 114 and 112 epicardial sites in MI+V animals and 92 and 100 sites in MI+GF rats. The values of both CV-l and CV-t were similar in the two groups (Fig. 3C), indicating that growth factor administration did not have any sizable effect on the spread of excitation at the epicardial surface.

The effective refractory period (ERP) was measured at 87, 113 and 92 epicardial sites in the MI, MI+V and MI+GF animals respectively. In the MI rats the average ERP value was 88.8±2.4 ms. After GF/V injection, ERP was about 30% longer in the MI+GF animals when compared with the MI+V group (Fig. 3D, \( p<0.001 \)). Interestingly, a longer ERP would reduce the probability of reentry circuits provided that CV increases or remains constant [43]. Thus, by the combined effect on conduction velocity and refractoriness, cytokine treatment is expected to reduce cardiac electrical instability. Indeed, stress induced VAEs were significantly reduced in GF treated animals (Fig. 2).

The degree of dispersion of ERP values and the duration of QTC interval were comparable in all animals (ERP dispersion: 11±1.5 ms in MI+V and 16±2.9 ms in MI+GF; QTC: 38.3±1 ms in MI+V and 39.4±12 ms in MI+GF) suggesting that (i) the influence of GFs on propensity to reentrant arrhythmias was not mediated by changes in the spatially non-uniform distribution of refractoriness and (ii) the longer ERP in MI+GF animals does not seem attributable to the longer duration of the recovery process.

**Quantitative RT-PCR measurements of \( I_{\text{to}} \) current subunits.** To determine whether an altered modulation of transient outward K current (\( I_{\text{to}} \)) could affect ERP, the major isoforms of the rat alpha (Kv4.2, Kv4.3, Kv1.4) and beta (KChIP2) subunits were measured at mRNA level in the peri-infarcted and remote (left and right) ventricular myocardium of the MI+V and MI+GF rats, in comparison with SO+V. By RT-PCR analysis, the mRNA expression for Kv4.2 and Kv4.3 alpha subunits in each myocardial region was alike in all animals (data not shown). Conversely, Kv1.4 and the accessory subunit of the K channel KChIP2 were significantly increased by MI (MI+V group), in the remote left and right ventricular myocardium (Kv1.4: about +50%, \( p<0.05 \) (Fig. 4A, C), and peri-infarcted and remote LV myocardium (KChIP2: about +100% and +20%, \( p<0.05 \) (Fig. 4B). In both cases, the rise was prevented by cytokines (MI+GF group).
Connexin43 expression. To confirm the positive effects on electrical function evoked by the intramyocardial injection of GFs, the Cx43 expression was evaluated in the infarcted and remote portions of the rat ventricles. The levels of Cx43 within the infarcted region were negligible in the MI group whereas local GF administration increased by about 10-fold (p<0.05) the expression of the gap-junctional protein (Fig. 5), suggesting a better electrical coupling within the scarred partially regenerated myocardium. Similar findings, although of lower magnitude (about 30% increase, p<0.05), were observed in the remote myocardium (Fig. 5).

2) Mechanical function

Echocardiographic and Hemodynamic Study. Before GF/V injection, echocardiographic measurements revealed the expected global deterioration in cardiac function in the MI group when compared with the SO group (Table S2). Two weeks after injection, in the MI+V animals, the morpho-functional properties of the left ventricle either remained unchanged or underwent a slight further deterioration (Table S2). In contrast, in the MI+GF rats, the treatment was followed by an improvement in the values of left ventricular end-diastolic diameter (LVEDD) and left ventricular end-diastolic volume (LVEDV), which approached those measured in the SO+V group (Table S2). These markers of unfavorable remodeling, representing the major anatomical determinants of heart failure, were attenuated in the MI+GF rats (Table 1).

In line with echocardiographic data, invasive hemodynamic measurements indicated that the impairment of dP/dt and left ventricular end-diastolic pressure (LVEDP) was correlated with post mortem determination of infarct size in the MI+V group (Fig. 7A–B) but not in the MI+GF group (Fig. 7A’–B’). These findings confirm that GF treatment abolishes the proportional deleterious effect of infarct size on the magnitude of LV mechanical performance.

3) Cardiac remodeling and regeneration

Cardiac Anatomy and Structure. We tested whether the beneficial effects of cytokine treatment on the electromechanical properties of the infarcted heart had a structural/anatomical counterpart. Compared with the SO+V animals, the MI+V group exhibited a significant increase in chamber volume associated with a moderate thinning of the left ventricular wall, resulting in a decreased mass-to-chamber volume ratio (Table 1). These markers of unfavorable remodeling, representing the major anatomical determinants of heart failure, were attenuated in the MI+GF rats (Table 1).

Myocardial fibrosis and small foci of collagen accumulation, uniformly distributed throughout the LV wall, were detected in the spared non-infarcted ventricular myocardium of both the MI+V and MI+GF groups. However, the volume fraction of interstitial fibrosis and the number of foci of replacement fibrosis were more than 2-fold lower in the treated MI+GF hearts (p<0.05; Fig. 8A–B).

The measurement in tissue sections of cross sectional area of transversally oriented spared myocytes showed that the average cell size was significantly increased only in the MI+V rats (p<0.05 vs. SO+V; Fig. 8C), indicating that reactive cellular hypertrophy was reduced by intramyocardial injection of GFs.
Immunohistochemical analysis of myocardial regeneration. Areas of myocardial regeneration were detected in the infarcted portion of GF treated rat hearts. Small BrdU+ myocytes, expressing N-Cadherin (Fig. 9A) and Cx43 (Fig. 9B) were observed, indicating that newly formed, electromechanically coupled cardiac myocytes resulted from local injection of GFs. Within the two weeks from cytokine injection a nearly 3-fold increase in cycling myocytes accumulated in MI+GF infarcts when compared with the MI+V ones (Fig. 9C). New myocytes properly integrated with the surrounding tissue were also present in the peri-infarcted and remote myocardium of treated animals, suggesting that local delivery of GFs exerted a global beneficial effect on the heart (Fig. 9C). Although similar findings could occasionally be detected in untreated chronic infarcts, the quantitative estimation clearly indicated that the regenerative processes were markedly enhanced in the MI+GF group in both the peri-infarcted and infarcted areas (Fig. 9C). Importantly, the newly formed myocardium was properly perfused, as indicated by the significant increase in the density of arteriolar profiles (two-fold) and BrdU+ endothelial cells (five-fold) (Fig. 9D–F).

Infarct size, as measured by the amount of myocytes lost 6 weeks after coronary artery ligation (4 weeks prior + 2 weeks after GF/V injection), was similar in the two experimental groups. As shown in Fig. 10A, nearly 4.5×10⁶ myocytes were lost in the MI+V and MI+GF hearts. Within the infarcted area, cytokine treatment promoted the formation of 15.6±2.5 mm³ of new myocardium in which an average of 5.9±0.1×10⁵ developing myocytes ranging in size from 200 to a maximum of 4000 μm³ were present (Fig. 10B). Most newly formed cardiomyocytes had a volume of less than 2000 μm³, although cytokine treatment was able to generate a consistent number of cells approaching a volume of 4000 μm³. This magnitude of myocardial regeneration resulted in a 21.2±1.7% replacement of the infarcted volume by newly formed myocardium. Conversely, myocardial repair in untreated infarcts was unremarkable. It is noteworthy that the generation of new myocytes increased linearly with the amount of cell loss in GF treated animals (Fig. 10C).

A similar reparative capacity was not observed in untreated rats. On the other hand, myocardial regeneration was associated with intense activation and translocation of resident progenitor cells (Fig. 10D). In comparison with MI+V, a significant (p<0.05) increase in the incidence of c-kit+ cells was produced by GFs in the infarcted, peri-infarcted and remote myocardium. Altogether these findings strongly suggest that GF-induced cardiac repair was mediated by a multipotent stem cell population.
Discussion

The induction or exacerbation of arrhythmias is a major concern in stem cell-based therapies for cardiac repair, and the effect of regenerative treatments on cardiac electrogensis is still under debate [5–15,46–47]. The present results demonstrate that intra-myocardial injection of HGF and IGF-1 in a rat model of healed myocardial infarction caused a significant decline in arrhythmias of conscious freely moving animals subjected to stressful conditions. Concurrently, the effective refractory period (ERP) at the ventricular surface of GF treated hearts was prolonged without changes in dispersion of refractoriness, QTc interval duration and mRNA levels of potassium channel α-subunits Kv4.2 and Kv4.3. In contrast, lower mRNA levels of α-subunit Kv1.4 and β-subunit KChIP2 were found in the remote and remote/peri-infarcted myocardium respectively.

In support of previous data [26–28], we also found that resident CPCs, stimulated locally by GF treatment, invaded the scarred myocardium and generated new electromechanically-connected myocytes and vessels. Additionally, experimental evidence was provided for a partial recovery of mechanical competence in the regenerated heart, associated with attenuation of unfavorable remodeling. Finally, newly formed myocardial structures together with a reduction in reactive cellular hypertrophy and interstitial fibrosis were detected in peri-infarcted and remote myocardium, suggesting that local delivery of GFs also exerted beneficial effects in the spared tissue.

Recovery of Electrical Function

Experimental electrophysiological studies aimed at assessing the proarrhythmic or antiarrhythmic potential of stem cell based

Figure 4. Expression of K channel isoforms. Quantification of Kv1.4 (A, C) and KChIP2 (B) mRNA levels, in ventricular myocardium. PI: peri-infarcted; Remote: spared left ventricular myocardium. Each bar represents the mean of 4 different samples in triplicate. * p<0.05 vs. SO+V and MI+GF. doi:10.1371/journal.pone.0017750.g004

Figure 5. Quantification of connexin43 protein expression. Western blot analysis of connexin43 protein expression in infarcted (I) and remote (R) left ventricular myocardium of MI+V and MI+GF hearts. MW = molecular weight marker; OD = optical density. * p<0.05 vs. MI+V. doi:10.1371/journal.pone.0017750.g005
therapies in vivo have been carried out mostly in anesthetized animals and in a few cases in conscious animals in baseline conditions [44]. While anesthesia can have confusing effects, the incidence of arrhythmias in baseline conditions is generally low. To circumvent these limitations, we measured the proneness to arrhythmias in conscious freely moving rats subjected to the resident-intruder test [32] which, by mimicking a natural situation, ensured that the mechanisms of arrhythmias acting during stress were in all probability the same which may trigger arrhythmias in everyday life of social animals. The procedure is known to consistently induce an intense activation of the autonomic nervous system, with a shift of the sympatho-vagal balance towards a sympathetic predominance, resulting in arrhythmias even in normal animals [45]. Stress-induced ventricular arrhythmias were reduced by about a half following GF injection, while no changes were observed in untreated rats, indicating a protective effect of local delivery of cytokines.

We found that dispersion of refractoriness was similar in treated and untreated animals, as were the indirect indexes of autonomic input to the heart (SDRR and r-MSSD), signifying that GFs did not alleviate arrhythmia susceptibility by affecting repolarization heterogeneity [46] or cardiac sympathetic activity [47].

Quantitative RT-PCR analysis of the genes encoding the Ca2+-independent transient outward potassium current (Ito) revealed that the transcript expression of Kv1.4 was up-regulated in the remote left ventricle only in untreated rats. Kv1.4 is the main channel subunit contributing to Ito during the embryonic development of mice and rats. After birth, Kv1.4 expression levels decrease, while Kv4.2 and Kv4.3 are up-regulated [48]. Importantly, cardiac hypertrophy induces a re-expression of Kv1.4 mRNA [49]. Furthermore, the rise in mRNA levels of potassium channel β-subunit KChIP2 produced by myocardial infarction was cancelled out by GF administration. Recent studies documented higher mRNA levels of KChIP2 in cardiac

---

Figure 6. Blunting effect of GF treatment on the correlation between infarct size and echocardiographic parameters. Linear correlations between infarct size and ejection fraction (EF) and left ventricular end-systolic volume (LVESV), in MI+V (A–B) and MI+GF (A’–B’) animals. The statistical significance of correlations was limited to the MI+V group.

doi:10.1371/journal.pone.0017750.g006
hypertrophy [50] although a full appreciation of this result is impossible, since to date the role of KChip(s) subunit(s) has not been clearly elucidated. In conclusion, the lower mRNA levels of Kv1.4 and KChIP2 subunits produced by GF injection might be associated with the reduced reactive cellular hypertrophy following cardiac repair. These findings, together with cardiac anatomical and morphometric data, indicate that GF treatment may succeed in partially controlling endogenous arrhythmic substrates by limiting myocardial damage, and reducing myocardial fibrosis and reactive cellular hypertrophy in the remote myocardium, thereby helping to prevent the occurrence of reentry circuits.

By using epicardial multiple-lead recording, we showed that cytokine injection resulted in a marked prolongation of ERP, while conduction velocity (CV) was unchanged. The combined effect of CV and ERP on impulse propagation is defined by the wavelength \( L = CV \times ERP \), implying that a longer \( L \) (by increasing CV and/or ERP) will reduce the likelihood that a single or multiple reentrant circuits can be accommodated by the heart [43]. Hence, ERP changes observed in GF treated rats could reduce the ability of cardiac tissue to elicit an abnormal propagated response by increasing \( L \), thus hampering reentry. The finding that epicardial QTc values were similar in all animals indicates that mechanisms other than lengthening of action potential duration (APD) were responsible for the longer ERP in GF treated rats. Accordingly, either membrane currents affecting APD were not influenced by GFs or, if they were, the net modification might not be large enough to manifest itself at the tissue level. Indeed, our data show that mRNA levels of the potassium channel \( \alpha \)-subunits Kv4.2 and

---

**Figure 7. Blunting effect of GF treatment on the correlation between infarct size and hemodynamic parameters.** Linear correlations between infarct size and maximum rate of ventricular pressure rise (+dP/dt) and left ventricular end-diastolic pressure (LVEDP), in MI+V (A–B) and MI+GF animals (A’–B’). The statistical significance of correlations was limited to the MI+V group.

doi:10.1371/journal.pone.0017750.g007

---
Kv4.3 did not exhibit any significant difference between untreated and HGF + IGF-1 treated hearts, suggesting that the transient outward potassium current ($I_{to}$), which contributes conspicuously to determine APD, was unaltered.

On the other hand, recent studies have demonstrated that IGF-1, alone or in combination with other growth factors, increases Cx43 expression in cardiac myocytes [10]. In support of these findings, we showed that GF administration significantly increased the expression of the gap-junctional protein Cx43, providing evidence for an increased electrical coupling within the scarred, partially regenerated myocardium as well as in the remote spared tissue. A better intercellular electrical connection is considered as being an important antiarrhythmic factor [10–15,51] and could also result in ERP prolongation. It has recently been remarked [52] that the amount of current needed for cardiac excitation by point stimulation is modulated by the properties of electrical coupling of the interconnected myocytes via gap-junctions. The smallest myocardial region capable of initiating a propagated action potential (“liminal length”) is inversely related to the extra- and intracellular resistivities, which are largely dependent on interstitial fibrosis and electrical coupling between myocytes respectively [52–53].

The role of myocardial geometry in the charge threshold for excitation was documented by computing the S-D curve, which shifted to the right when the “liminal length” increased (i.e. reduced excitability) and to the left when it decreased (i.e. increased excitability) [53]. Changes in “liminal length” resulting from different degrees of electrical coupling between myocytes are also expected to affect cardiac refractoriness, which will be increased by an increase in “liminal length” and reduced by its reduction. Concurrently, the longer ERP and the associated

Table 1. Left ventricular geometry and infarct size.

|                      | SO+V (n = 15) | MI+V (n = 23) | MI+GF (n = 22) |
|----------------------|---------------|---------------|----------------|
| LV mass (mm$^3$)     | 769±43        | 1046±35 *     | 1031±17 *      |
| LV wall thickness (mm)| 2.2±0.1      | 2.0±0.1       | 2.2±0.1        |
| LV chamber diameter (mm)| 5.5±0.2      | 7.2±0.2 *     | 6.7±0.2 *      |
| LV chamber volume (mm$^3$)| 199±11      | 413±25 *     | 336±18 * / #   |
| mass/chamber volume  | 4.1±0.1      | 2.4±0.1 *     | 2.9±0.2 *      |
| Infarct size (%)     | 19.4±3.2     | 19.9±2.9      |

Mean values ± SE of left ventricular (LV) geometrical properties measured in SO+V, MI+V and MI+GF groups.
*p<0.01 significant differences vs. SO+V group;  # p<0.05 significant differences vs. MI+V.
doi:10.1371/journal.pone.0017750.t001

Figure 8. Myocardial fibrosis and left ventricular myocyte size. Mean values ± SE of volume fraction of fibrosis (A) and numerical density of fibrotic foci (B), morphometrically evaluated in the remote left ventricular (LV) myocardium of MI+V and MI+GF hearts. In (C), mean values ± SE of the LV myocyte cross-sectional area. * p<0.05 vs. MI+V;  # p<0.05 vs. SO+V.
doi:10.1371/journal.pone.0017750.g008
tendential shift to the right of the S-D curve induced by HGF+IGF-1 administration might be attributed to the higher expression of Cx43 and the longer "liminal length" resulting from an enhanced cardiomyocyte interconnection.

Cardiac Regeneration, ventricular remodeling and recovery of mechanical function

Recent studies in animal models of chronic myocardial infarction [28] have documented a negative impact of the scarred myocardium on the migration and engraftment of CPCs when compared with acute infarcts. Yet, in spite of the less favorable environment related to chronic collagen deposition after infarction, GF-activated CPCs retain the ability to infiltrate the scar, digest part of the connective tissue, and form cardiomyocytes and coronary vessels via enhanced activity of metalloproteases. In support of these findings [28], we showed that HGF and IGF-1 administration triggered the proliferation and mobilization of CPCs, leading to newly formed functionally competent myocardial tissue. Importantly, proliferating myocytes expressed N-Cadherin and Cx43 and linearly increased with the amount of cell loss. Coronary arterioles and capillary structures were concurrently produced with myocytes, tending to preserve blood supply and oxygen diffusion to the surrounding cells. Ultimately, GF-induced activation of CPCs elicited a sustained regenerative response that resulted in a 20% rescue of the infarct by replacing fibrotic tissue with viable myocardium.

GF treatment attenuated ventricular dilation, increased ventricular mass/chamber volume ratio, and reduced collagen accumulation in the spared myocardium more than 2-fold while restraining the hypertrophic response of myocytes to the segmental loss of cells.

As shown by the echocardiography findings, post-MI ventricular dysfunction tended to recover in GF treated infarcts. Furthermore, echocardiographic and hemodynamic data documented that the significant, negative correlation of cardiac mechanical function with the extension of the infarcted area in untreated animals was lost as a result of intramyocardial injection of GFs.
It could be argued that a single injection of cells or GFs hardly promotes a sustained and prolonged cardiac repair in the absence of a robust activation of autocrine/paracrine processes. Moreover, the question remains as to whether a 20% recovery of myocardial mass within the infarct, mostly consisting of small contractile cells, is sufficient to prevent the evolution of myocardial infarction toward cardiac decompensation. However, infarct size is proportional to the number of lost cardiomyocytes, representing the major determinant of unfavorable LV remodeling and its chronic evolution toward heart failure [40]. Hence it is of relevance that the GF-mediated generation of young functionally competent cardiomyocytes succeeds in making cardiac function and anatomy independent of the amount of tissue lost by the occlusion of the supplying coronary artery. These results suggest that locally delivered GFs, by reversing the hostile microenvironment of scarred myocardium, promote a cardiac repair which is proportional to tissue demand. Intriguingly, this phenomenon has been observed in clinical experience of cell therapy for ischemic cardiomyopathy [54–56], documenting greater improvement in global cardiac function in patients who had a lower ejection fraction at baseline. Thus, regenerative approaches seem to exert a more beneficial effect on larger myocardial infarcts.

**Conclusion**

Altogether, this study indicates that local injection in scarred infarcts of active peptides able to recapitulate an endogenous cell program aimed at generating functionally competent myocardium, besides having a positive impact on the mechanical properties of the injured heart, results in a significant decline in proneness to arrhythmias. Both ERP prolongation (likely mediated by improved intercellular electrical coupling leading to increased liminal length for impulse formation) and positive ventricular structural remodeling contribute to the reduced ventricular arrhythmogenesis.

**Supporting Information**

File S1 Detailed description of the experimental design, surgical procedures, electrophysiological measurements (telemetry ECGs and multiple-lead epicardial recording), echocardiographic and hemodynamic measurements, morphometrical and immunohisto-
References

1. Marbán E, Cheng K (2010) Heart to heart: The elusive mechanism of cell therapy. Circulation 121: 1981–1984.
2. Dimmeler S, Zeiher AM, Schneider MD (2005) Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest 115: 572–583.
3. Jogerst SJ, Hatzopoulos PK (2009) Stem cell therapy for cardiac repair: benefits and barriers. Expert Rev Mol Med 11: e20.
4. Lerì A, Kajstura J, Anversa P (2005) Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev 85: 1373–1416.
5. Chen HS, Kim C, Mersola M (2009) Electrophysiological challenges of cell-based myocardial repair. Circulation 120: 2496–2506.
6. Ly HQ, Natel S (2009) Stem cells are not proarrhythmic: letting the genie out of the bottle. Circulation 119: 1824–1831.
7. Macia E, Boyden PA (2009) Stem cell therapy is proarrhythmic. Circulation 119: 1814–1823.
8. Menasché P (2009) Stem cell therapy for heart failure: are arrhythmias a real safety concern? Circulation 119: 2735–2740.
9. Smith RR, Barile L, Messina E, Marban E (2008) Stem cells in the heart: what's the buzz all about? Part 2: arrhythmic risks and clinical studies. Heart Rhythm 5: 480–487.
10. Hahn JY, Cho HJ, Kang HJ, Kim TS, Kim MH, et al. (2008) Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 51: 933–943.
11. Kuhlmann MT, Kirchhof P, Klocke R, Hasib H, Stypmann J, et al. (2006) G-CSF/SDF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis. J Exp Med 203: 87–97.
12. Mills WR, Mal N, Kiedowski MJ, Ungrl R, Forush F, et al. (2007) Stem cell therapy enhances electrical viability in myocardial infarction. J Mol Cell Cardiol 42: 304–314.
13. Roelf W, Leuvalter T, Sasse P, Tallinn YN, Choi BR, et al. (2007) Engraftment of connexin43-expressing cells prevents post-infarct arrhythmia. Nature 450: 819–824.
14. Gepstein L, Ding C, Rehemedna D, Wilson EE, Yankelou L, et al. (2010) In vivo assessment of the electrophysiological integration and arrhythmogenic risk of myocardial cell transplantation strategies. Stem Cells 28: 2151–2161.
15. Wang D, Zhang F, Shen W, Chen M, Yang B, et al. (2010) Mesenchymal stem cell injection ameliorates the inducibility of ventricular arrhythmias after myocardial infarction in rats. Int J Cardiol Epic of print: DOI: 10.1016/j.jcard.2010.07.025.
16. Beltrami AP, Barcucci I, Torrella D, Baker M, Limana F, et al. (2003) Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114: 763–774.
17. Oh H, Bradu FE, Gallardo TD, Nakamura T, Gausin V, et al. (2003) Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A 100: 12313–12318.
18. Martin CM, Meeson AP, Robertson SM, Hawke TJ, Richardson JA, et al. (2004) Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev Biol 265: 202–273.
19. Messina E, De Angela L, Friti G, Morreone S, Chimienti S, et al. (2004) Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 95: 911–921.
20. Laugwitz KL, Moretti A, Lami J, Gruber P, Chen Y, et al. (2005) Postnatal id1+-cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 433: 47–65.
21. Limana F, Zachos A, Micmi D, Mangoni A, Borrello G, et al. (2007) Identification of myocardial and vascular precursor cells in human and mouse epicardium. Circ Res 101: 1255–1265.
22. Doris DR, Kizana E, Terrovitis J, Barth AS, Zhang Y, et al. (2010) Isolation and expansion of functionally-competent cardiac progenitor cells directly from heart. J Mol Cell Cardiol 49: pp 312–321.
23. Quaini F, Urbanek K, Beltrami AP, Finao N, Beltrami CA, et al. (2002) Chimerism of the transplanted heart. N Engl J Med 346: 5–15.
24. Chamulau SA, Vrijen KR, Rokosh DG, Tang XL, Pek J, et al. (2009) Cell therapy for ischaemic heart disease: focus on the role of resident cardiac stem cells. Neth Heart J 17: 199–207.
25. Dawn B, Stein AB, Urbanek K, Rota M, Whang B, et al. (2005) Cardiac stem cells delivered intravenously traverses the vessel barrier, regenerates infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A 102: 3766–3771.
26. Urbanek K, Rota M, Casparaca S, Bearzi C, Nasimbene A, et al. (2005) Cardiac stem cells possess growth factors-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res 97: 663–673.
27. Linke A, Muller P, Nurzynska D, Casarsa C, Torella D, et al. (2005) Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A 102: 8966–8971.
28. Rota M, Padin-Inuega ME, Misso Y, De Angelis A, Maestroni S, et al. (2008) Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ Res 103: 107–116.
29. Ghiorghie MD, Ronse RO (1990) Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97: 282–289.
30. Kjekshus J (1990) Arrhythmias and mortality in congestive heart failure. Am J Cardiol 65: 421–425.
31. Nogue M, Sella D, Medei D, Gallo P, Aiim B, et al. (1996) Electrode positioning for reliable telemetry ECG recordings during social stress in unrestrained rats. Physiol Behav 60: 1397–1401.
32. Martinez M, Calvo Torrent A, Pico Alfonso MA (1998) Social defeat and subordination as models of social stress in laboratory rodents: a review. Agress Behav 24: 241–256.
33. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (1996) Heart rate variability. Standards of measurement,physiological interpretation, and clinical use. Circulation 93: 1043–1075.
34. Pollick C, Hale SL, Klöner RA (1995) Ecocardiographic and cardiac Doppler assessment of m. J Am Soc Echocardiogr 8: 602–610.
35. Macchi E, Cavallier M, Stilli D, Musso E, Baruff S, et al. (1998) High-density epicardial mapping during current injection and ventricular activation in rat hearts. Am J Physiol Heart Circ Physiol 275: H1886–1897.
36. Ogawa S, Furiuno I, Sato Y, Yoh S, Sarks K, et al. (1991) Quantitative indices of dispersion of refractoriness for identification of propensity to re-entrant ventricular tachycardia in a canine model of myocardial infarction. Cardiovasc Res 25: 376–383.
37. Mitchell GF, Jeron A, Koren G (1998) Measurement of heart rate and Q-T interval during submaximal exercise. J Clin Monit Cardiovasc Technol 14: 114: 763–776.
38. Kjekshus J (1990) Arrhythmias and mortality in congestive heart failure. Am J Cardiol 65: 421–425.
39. Dodge HT, Baxley WA (1969) Left ventricular volume and mass and their relationship to subendocardial ischemia. Circ Res 25: 378–383.
40. Mitchell GF, Jeron A, Koren G (1998) Measurement of heart rate and Q-T interval during submaximal exercise. J Clin Monit Cardiovasc Technol 14: 114: 763–776.
41. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, et al. (2001) Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 98: 10344–10349.

42. Stilli D, Lagrasta C, Berni R, Bocchi L, Savi M, et al. (2007) Preservation of ventricular performance at early stages of diabetic cardiomyopathy involves changes in myocyte size, number and intercellular coupling. Basic Res Cardiol 102: 488–499.

43. van Rijen HV, van Veen TA, Gros D, Wilders R, de Bakker JM (2006) Connexins and cardiac arrhythmias. Adv Cardiol 42: 150–160.

44. Kolettis TM (2006) Arrhythmogenesis after cell transplantation post-myocardial infarction. Four burning questions-and some answers. Cardiovasc Res 69: 299–301.

45. Stilli D, Berni R, Bocchi L, Zaniboni M, Cacciani F, et al. (2004) Vulnerability to ventricular arrhythmias and heterogeneity of action potential duration in normal rats. Exp Physiol 89: 387–396.

46. Fukushima S, Varela-Carver A, Coppen SR, Yamahara K, Felkin LE, et al. (2007) Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation 115: 2254–2261.

47. Pak HQ, Quyyun M, Kim DT, Hamabe A, Miyazaki Y, et al. (2003) Mesenchymal stem cell injection induces cardiac nerve sprouting and increased tenascin expression in a swine model of myocardial infarction. J Cardiac Electrophysiol 14: 841–848.

48. van der Heyden MA, Wijshoven TJ, Opthof T (2006) Molecular aspects of adrenergic modulation of the transient outward current. Cardiovasc Res 71: 430–442.

49. Marionneau C, Beuret S, Flagg TP, Pâgrom TK, Deomolnhe S, et al. (2008) Distinct cellular and molecular mechanisms underlie functional remodeling of repolarizing K+ currents with left ventricular hypertrophy. Circ Res 102: 1406–1415.

50. Tozakidou M, Goltz D, Hagenstrom T, Badack MK, Vizutham H, et al. (2010) Molecular and functional remodeling of I(to) by angiotensin II in the mouse left ventricle. J Mol Cell Cardiol 48: 140–151.

51. Duffy HS (2008) Cardiac Connections-The Antiarrhythmic Solution? N Engl J Med 358: 1397–1398.

52. Fozzard HA (2001) Gap junctions and liminal length in hypertrophy: something old and something new. J Cardiovasc Electrophysiol 12: 836–837.

53. Fozzard HA, Schoenberg M (1972) Strength-duration curves in cardiac Purkinje fibres: effects of liminal length and charge distribution. J Physiol 226: 593–616.

54. Schachinger V, Assman B, Britten MB, Honold J, Lehmann R, et al. (2004) Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 44: 1690–1699.

55. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, et al. (2006) Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355: 1210–1221.

56. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, et al. (2006) Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 27: 2773–2783.